# Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

> **NCT02896192** · PHASE3 · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Pro-opiomelanocortin (POMC) Deficiency Obesity

## Interventions

- **DRUG:** Setmelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02896192
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-14
- **Primary completion:** 2020-05-25
- **Final completion:** 2020-05-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896192, "Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02896192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*